Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, has announced a temporary trading halt of its ordinary shares on Euronext Paris starting July 24, 2025, at 9:00 a.m. CEST. The suspension is related to the company's previously announced public offering of American Depositary Shares (ADS) in the United States.
The trading halt will allow for investor allocation confirmations and pricing announcement of the U.S. offering. Each ADS represents one ordinary share with a nominal value of 鈧�0.01. Trading is expected to resume on the same day at approximately 3:30 p.m. CEST.
Abivax (Euronext Paris: ABVX), un'azienda biotecnologica in fase clinica, ha annunciato una sospensione temporanea della negoziazione delle sue azioni ordinarie su Euronext Paris a partire dal 24 luglio 2025, alle ore 9:00 CEST. La sospensione 猫 legata all'offerta pubblica di American Depositary Shares (ADS) negli Stati Uniti precedentemente annunciata dalla societ脿.
La sospensione permetter脿 di confermare l'allocazione agli investitori e di annunciare il prezzo dell'offerta negli USA. Ogni ADS rappresenta un'azione ordinaria con un valore nominale di 0,01 鈧�. Si prevede che la negoziazione riprenda lo stesso giorno intorno alle 15:30 CEST.
Abivax (Euronext Paris: ABVX), una empresa biotecnol贸gica en etapa cl铆nica, ha anunciado una suspensi贸n temporal de la negociaci贸n de sus acciones ordinarias en Euronext Paris a partir del 24 de julio de 2025 a las 9:00 a.m. CEST. La suspensi贸n est谩 relacionada con la oferta p煤blica previamente anunciada de American Depositary Shares (ADS) en Estados Unidos.
La suspensi贸n permitir谩 confirmar la asignaci贸n a los inversores y anunciar el precio de la oferta en EE. UU. Cada ADS representa una acci贸n ordinaria con un valor nominal de 0,01 鈧�. Se espera que la negociaci贸n se reanude el mismo d铆a alrededor de las 3:30 p.m. CEST.
Abivax (Euronext Paris: ABVX)電� 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厡韥� 旮办梾鞙茧, 2025雲� 7鞗� 24鞚� 鞓れ爠 9鞁� CEST攵�韯� Euronext Paris鞐愳劀 氤错喌欤� 瓯半灅毳� 鞚检嫓 欷戨嫧頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 欷戨嫧鞚� 須岇偓臧� 鞚挫爠鞐� 氚滍憸頃� 氙戈淡 雮� American Depositary Shares(ADS) 瓿店皽 氇瓿� 甏�霠澊 鞛堨姷雼堧嫟.
瓯半灅 欷戨嫧鞚� 韴瀽鞛� 氚办爼 頇曥澑 氚� 氙戈淡 瓿店皽 氇 臧�瓴� 氚滍憸毳� 鞙勴暣 鞚措（鞏挫雼堧嫟. 臧� ADS電� 氇呺臧� 0.01鞙犽鞚� 氤错喌欤� 1欤茧ゼ 雮橅儉雰呺媹雼�. 瓯半灅電� 臧欖潃 雮� 鞓ろ泟 3鞁� 30攵勱步 CEST鞐� 鞛皽霅� 鞓堨爼鞛呺媹雼�.
Abivax (Euronext Paris : ABVX), une soci茅t茅 de biotechnologie en phase clinique, a annonc茅 une suspension temporaire de la cotation de ses actions ordinaires sur Euronext Paris 脿 partir du 24 juillet 2025 脿 9h00 CEST. Cette suspension est li茅e 脿 l'offre publique d'American Depositary Shares (ADS) aux 脡tats-Unis, annonc茅e pr茅c茅demment par la soci茅t茅.
Cette suspension permettra de confirmer l'allocation aux investisseurs et d'annoncer le prix de l'offre am茅ricaine. Chaque ADS repr茅sente une action ordinaire d'une valeur nominale de 0,01 鈧�. La reprise des 茅changes est pr茅vue le m锚me jour vers 15h30 CEST.
Abivax (Euronext Paris: ABVX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, hat eine vor眉bergehende Aussetzung des Handels mit seinen Stammaktien an der Euronext Paris ab dem 24. Juli 2025 um 9:00 Uhr MESZ angek眉ndigt. Die Aussetzung steht im Zusammenhang mit dem zuvor angek眉ndigten 枚ffentlichen Angebot von American Depositary Shares (ADS) in den USA.
Die Handelspause erm枚glicht die Best盲tigung der Investorenallokation und die Bekanntgabe des Preises des US-Angebots. Jede ADS repr盲sentiert eine Stammaktie mit einem Nennwert von 0,01 鈧�. Der Handel wird voraussichtlich am selben Tag gegen 15:30 Uhr MESZ wieder aufgenommen.
- Company pursuing U.S. market expansion through ADS offering
- Strategic move to access U.S. capital markets
- Temporary trading suspension may cause short-term market disruption
- Potential dilution for existing shareholders through ADS offering
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
PARIS, France, July 24, 2025 鈥� 07:30 a.m. (CEST) 鈥� Abivax SA (Euronext Paris: FR0012333284 鈥� ABVX) (鈥�Abivax鈥� or the 鈥�Company鈥�), a clinical-stage biotechnology company focused on developing therapeutics that harness the body鈥檚 natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (鈥�Euronext Paris鈥�) will be temporarily halted, at the Company鈥檚 request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share,
This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today, July 24, 2025, at approximately 3:30 p.m. (CEST).
***
About Abivax
Abivax听is a clinical-stage biotechnology company focused on developing therapeutics that harness the body鈥檚 natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in听France听and听the United States, Abivax鈥檚 lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contacts:
| Abivax Investor Relations Patrick Malloy [email protected] +1 847 987 4878 | 听 |
***
Disclaimers
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
FAQ
Why did Abivax (ABVX) halt trading on Euronext Paris on July 24, 2025?
When will Abivax (ABVX) resume trading on Euronext Paris?
What is the structure of Abivax's ADS offering in the United States?
What is Abivax's main business focus?
